Skip to main content

Advertisement

SpringerLink
Log in

Pilot study of pegylated interferon alpha-2a treatment during chemo- and radiotherapy and post-remission maintenance in patients with EBV-positive extranodal NK/T cell lymphoma

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The role of the Epstein–Barr virus (EBV) in the pathogenesis of extranodal natural killer/T-cell lymphoma (ENKTCL), and its resistance to chemotherapy raises the possibility of antiviral therapeutic strategies. The aim of this prospective pilot study was to evaluate the feasibility and effectiveness of antiviral treatment using pegylated interferon alpha-2a (pIFN α-2a) as an adjunct to induction and maintenance therapy in patients with ENKTCL. A total of seven patients with newly diagnosed EBV-positive ENKTCL were enrolled. Pegylated IFN α-2a was administered during induction chemoradiotherapy. If patients achieved a partial or complete response (PR or CR, respectively), high-dose chemotherapy with autologous stem cell transplantation (HDT/SCT) was given. After transplantation, maintenance therapy included pIFN α-2a for 3 years. Of the patients available for evaluation, all achieved a CR or PR after induction therapy but one patient relapsed before HDT/SCT. The event free survival and overall survival at 3 years were 50.0 ± 20.4% and 66.7 ± 19.2%, respectively. The 3-year disease-free survival after transplantation of the patients that received maintenance therapy was 80.0 ± 17.9%. The results of this pilot study indicated that pIFN α-2a containing induction and maintenance therapy was feasible and effective for ENKTCL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ishii H, Ogino T, Berger C, Kochli-Schmitz N, Nagato T, Takahara M, Nadal D, Harabuchi Y (2007) Clinical usefulness of serum EBV DNA levels of bamhi w and lmp1 for nasal NK/T-cell lymphoma. J Med Virol 79(5):562–572

    Article  PubMed  CAS  Google Scholar 

  2. Greer JP (2006) Therapy of peripheral T/NK neoplasms. Hematology Am Soc Hematol Educ Program 331–337

  3. Huang WT, Chang KC, Huang GC, Hsiao JR, Chen HH, Chuang SS, Chen TY, Su WC, Tsao CJ (2005) Bone marrow that is positive for EBV-encoded RNA-1 by in situ hybridization is related with a poor prognosis in patients with extranodal natural killer/T-cell lymphoma, nasal type. Haematologica 90(8):1063–1069

    PubMed  CAS  Google Scholar 

  4. Ortaldo JR, Mason A, Rehberg E, Moschera J, Kelder B, Pestka S, Herberman RB (1983) Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells. J Biol Chem 258(24):15011–15015

    PubMed  CAS  Google Scholar 

  5. Greiner JW, Guadagni F, Noguchi P, Pestka S, Colcher D, Fisher PB, Schlom J (1987) Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science (New York, NY) 235(4791):895–898

    Article  CAS  Google Scholar 

  6. Pestka S, Krause CD, Walter MR (2004) Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202:8–32

    Article  PubMed  CAS  Google Scholar 

  7. Faro A (1998) Interferon-alpha and its effects on post-transplant lymphoproliferative disorders. Springer Semin Immunopathol 20(3–4):425–436

    Article  PubMed  CAS  Google Scholar 

  8. Garner JG, Hirsch MS, Schooley RT (1984) Prevention of Epstein–Barr virus-induced b-cell outgrowth by interferon alpha. Infect Immunity 43(3):920–924

    CAS  Google Scholar 

  9. Cho SG, Koh YB, Chang HS, Park G, Kang CS, Park JW, Min WS (2005) Successful treatment with splenectomy and interferon alpha against recurred hemophagocytic syndrome in remission state of anaplastic large cell lymphoma following high-dose therapy and autologous peripheral blood stem cell transplantation. Eur J Haematol 74(3):259–262

    Article  PubMed  Google Scholar 

  10. Cheung MM, Chan JK, Lau WH, Foo W, Chan PT, Ng CS, Ngan RK (1998) Primary non-Hodgkin’s lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 16(1):70–77

    PubMed  CAS  Google Scholar 

  11. Au WY, Lie AK, Liang R, Kwong YL, Yau CC, Cheung MM, Ngan KC, Lau WH, Wong KH, Yiu HY, Cheng HC, Au KH, Chan JK (2003) Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol 14(11):1673–1676

    Article  PubMed  CAS  Google Scholar 

  12. Longo DL, DeVita VT Jr, Duffey PL, Wesley MN, Ihde DC, Hubbard SM, Gilliom M, Jaffe ES, Cossman J, Fisher RI et al (1991) Superiority of promace-cytabom over promace-mopp in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol 9(1):25–38

    PubMed  CAS  Google Scholar 

  13. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586

    Article  PubMed  Google Scholar 

  14. Ruiz G, Pena P, de Ory F, Echevarria JE (2005) Comparison of commercial real-time PCR assays for quantification of Epstein–Barr virus DNA. J Clin Microbiol 43(5):2053–2057

    Article  PubMed  CAS  Google Scholar 

  15. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP (1993) Comparison of a standard regimen (chop) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. New Engl J Med 328(14):1002–1006

    Article  PubMed  CAS  Google Scholar 

  16. Au WY, Pang A, Choy C, Chim CS, Kwong YL (2004) Quantification of circulating Epstein–Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 104(1):243–249

    Article  PubMed  CAS  Google Scholar 

  17. Feng WH, Israel B, Raab-Traub N, Busson P, Kenney SC (2002) Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res 62(6):1920–1926

    PubMed  CAS  Google Scholar 

  18. Sharp NA, Arrand JR, Clemens MJ (1989) Epstein–Barr virus replication in interferon-treated cells. J Gen Virol 70(Pt 9):2521–2526

    Article  PubMed  CAS  Google Scholar 

  19. Delcayre AX, Lotz M, Lernhardt W (1993) Inhibition of Epstein–Barr virus-mediated capping of CD21/CR2 by alpha interferon (IFN-alpha): immediate antiviral activity of IFN-alpha during the early phase of infection. J Virol 67(5):2918–2921

    PubMed  CAS  Google Scholar 

  20. Taguchi Y, Purtilo DT, Okano M (1994) The effect of intravenous immunoglobulin and interferon-alpha on Epstein-Barr virus-induced lymphoproliferative disorder in a liver transplant recipient. Transplantation 57(12):1813–1815

    PubMed  CAS  Google Scholar 

  21. O’Brien S, Bernert RA, Logan JL, Lien YH (1997) Remission of posttransplant lymphoproliferative disorder after interferon alfa therapy. J Am Soc Nephrol 8(9):1483–1489

    PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by grants from the Korea Science and Engineering Foundation (R11-2002-098-08004-0) and from the Catholic Institute of Cell Therapy Basic Science Programs Foundation during the program year 2007. The study was, in part, sponsored by Roche Pharmaceutical.

Author information

Authors and Affiliations

  1. Department of Hematology/Oncology, KonKuk University Medical Center, KonKuk University, Seoul, South Korea

    Sung-Yong Kim

  2. Catholic Blood and Marrow Transplantation Center, Seoul St. Mary’s Hospital, The Catholic University of Korea, Banpo 4-dong, Seocho-gu, Seoul, 137-701, South Korea

    Seok-Goo Cho, Chang-Ki Min, Jong-Wook Lee & Woo-Sung Min

  3. Department of Otolaryngology-Head and Neck Surgery, The Catholic University of Korea, Seoul, South Korea

    Sung-Won Kim

  4. Department of Radiation Oncology, The Catholic University of Korea, Seoul, South Korea

    Byung-Ok Choi

  5. Department of Pathology, The Catholic University of Korea, Seoul, South Korea

    Kyung-Sin Park

  6. Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea

    Jihyang Lim & Yong-Goo Kim

Authors
  1. Sung-Yong Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seok-Goo Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sung-Won Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Byung-Ok Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kyung-Sin Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jihyang Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chang-Ki Min
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yong-Goo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jong-Wook Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Woo-Sung Min
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seok-Goo Cho.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, SY., Cho, SG., Kim, SW. et al. Pilot study of pegylated interferon alpha-2a treatment during chemo- and radiotherapy and post-remission maintenance in patients with EBV-positive extranodal NK/T cell lymphoma. Ann Hematol 90, 693–699 (2011). https://doi.org/10.1007/s00277-010-1114-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-010-1114-y

Keywords

Search

Navigation